Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium pyruvate - EmphyCorp

Next Previous
Drug Profile

Sodium pyruvate - EmphyCorp

Alternative Names: EmphyClear COPD Oral Spray; EmphyClear COPD/Asthma Spray; N115; N115 Non-Steroidal Nasal Spray; Rx N115 non-steroidal nasal spray; Sodium pyruvate inhalation - EmphyCorp; Sodium pyruvate nasal spray

Latest Information Update: 28 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emphycorp
  • Developer Cellular Sciences; Emphycorp
  • Class Antiasthmatics; Antifibrotics; Antivirals; Sodium compounds
  • Mechanism of Action Interleukin 6 inhibitors; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Cystic fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Interstitial lung diseases
  • Phase II/III COVID 2019 infections; Influenza virus infections; Post acute COVID 19 syndrome
  • Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • No development reported Lung disorders

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Prevention) in USA (Inhalation, Spray)
  • 12 Aug 2022 Cellular Sciences completes a phase-II/III trial in COVID-2019 infections in USA (Inhalation, In adults) (NCT04824365)
  • 12 Aug 2022 Cellular Sciences completes a phase-II/III trial in Influenza virus infections in USA (Inhalation, In adults) (NCT04824365)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top